Skip to Content

SARS-CoV-2 Seroprevalence Low in U.S. From July to Sept. 2020

THURSDAY, Dec. 3, 2020 -- Most people in the United States did not have detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies as of September 2020, according to a study published online Nov. 24 in JAMA Internal Medicine.

Kristina L. Bajema, M.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues conducted a repeated cross-sectional study across all 50 states, the District of Columbia, and Puerto Rico to estimate the prevalence of persons with SARS-CoV-2 antibodies. A total of 177,919 samples were obtained during July 27 to Aug. 13, Aug. 10 to Aug. 27, Aug. 24 to Sept. 10, and Sept. 7 to Sept. 24, 2020. The proportion of people previously infected with SARS-CoV-2 as measured by the presence of antibodies to SARS-CoV-2 was examined.

The researchers found that over the four collection periods, jurisdiction-level seroprevalence varied from less than 1 percent to 23 percent. Less than 10 percent of people had detectable SARS-CoV-2 antibodies in 42 of 49 jurisdictions with sufficient samples to estimate seroprevalence across all periods. There was variation noted in seroprevalence estimates between sexes, across age groups, and between metropolitan/nonmetropolitan areas. In all jurisdictions, the changes from period 1 to 4 were less than 7 percentage points, with variation across sites.

"Our results reinforce the need for continued public health preventive measures, including the use of face masks and social distancing, to limit the spread of SARS-CoV-2 in the United States," the authors write.

ICF, Quest Diagnostics, and BioReference Laboratories were awarded federal contracts from the CDC for the execution of this project.

Abstract/Full Text


© 2021 HealthDay. All rights reserved.

Posted: December 2020

Read this next

Cancer Screening, Diagnoses Down During Early Pandemic

FRIDAY, Jan. 22, 2021 -- There was a significant decrease in the number of patients undergoing screening tests for cancer and in the number of resulting diagnoses of cancerous and...

Bamlanivimab + Etesevimab Reduces SARS-CoV-2 Viral Load

FRIDAY, Jan. 22, 2021 -- Treatment with bamlanivimab and etesevimab, but not monotherapy with bamlanivimab, is associated with a reduction in severe acute respiratory syndrome...

Total Pediatric ED Visits Decreased in 2020 Versus 2018, 2019

FRIDAY, Jan. 22, 2021 -- There was a decrease in the total number of pediatric emergency department visits in 2020, but the proportion of trauma-related visits increased,...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.